EurkeAlert! looks at progress in halting the progression of an animal model of Alzheimer's disease: "Stimulation of a receptor in the brain that controls insulin responses has been shown to halt or diminish the neurodegeneration of Alzheimer's disease ... peroxisome-proliferator activated receptor (PPAR) agonists prevent several components of neurodegeneration and preserve learning and memory in rats with induced Alzheimer's disease (AD). ... This raises the possibility that you can treat patients with mild cognitive impairment who have possible or probable Alzheimer's disease." This follows on from previous work in which "the researchers demonstrated that Alzheimer's is a brain-specific neuroendocrine disorder, or a Type 3 diabetes, distinct from other types of diabetes." Lo and behold: benefits from a class of compound already in use for type 2 diabetes. Do more readily available anti-diabetes strategies also hold off Alzheimer's? Time, and further research, will tell.